1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Exosomes Market - Growth, Trends, and Forecast (2019 - 2024)

Exosomes Market - Growth, Trends, and Forecast (2019 - 2024)

  • October 2019
  • 109 pages
  • ID: 5826220
  • Format: PDF
  • By Mordor Intelligence LLP

Summary

Table of Contents

Search Inside

Market Overview
The exosomes market is expected to register a CAGR of nearly 18.0% during the forecast period, 2019-2024.

- Certain factors that are driving the market growth include rising prevalence of cancer, technological advancements in exosomes isolation and analytical procedures, increasing government initiatives and funding for exosome research, and increasing advanced applications of exosomes.
- The growing prevalence of cancer patients has a direct impact on the increased demand for the exosomes market.
- According to the 2012 report of the World Health Organization (WHO), there were 14 million new cases of cancer, and this is expected to rise by about 70% over the next two decades.
- In the United States, as per the National Cancer Institute report of 2018, an estimated 1.7 million new cases of cancer were diagnosed in the country and nearly 0.6 million patients died due to cancer.
- Exosomes extracted from cow milk is being used for the delivery of therapeutic molecules against lung and breast cancers.
- Exosomes derived from specific sites of the body are promising candidates for anti-cancer vaccines, due to the enhanced passive targeting, owing to its small size, indigenous nature, and the ability to cross the biological barriers. Thus, the increase in the cancer cases in the hospitals directly increases the demand for exosomes in diagnosis as well as therapeutics.
- However, a number of technical difficulties need to be addressed for the successful implementation of exosomes in various applications. This is one of the primary hindrances for the growth of the exosomes market.
- Some of the major difficulties include optimization of purification, increasing the homogeneity of exosomes, and efficient transfection strategies. This is further accompanied by a lack of technical information, like the type of rotor, diameter, volume, and viscosity of the sample, which restricts the maximum utilization of exosomes.
- The cumbersome nature of methods for isolation/purification and inability to distinguish between different cancer stages with an incomplete understanding of the immune system limits the exosomes market.
- Other factors limiting the growth of this market are the lack of skilled professionals and stringent regulatory requirements for the approval and commercialization of exosome products.

Scope of the Report
Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture, and are created upon the fusion of the multivesicular body (MVB), an intermediate endocytic compartment, with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication.

Key Market Trends
Ultracentrifugation is Expected to Hold Significant Market Share in the Isolation Method Segment

Centrifugation is employed to analyze the hydrodynamic properties of polymeric materials, including biopolymers, such as nucleic acids and proteins. In isolation methods, ultracentrifugation-based exosomes isolation (in particular differential) is considered as the gold standard, which generates the exceptionally high centrifugal forces of up to 1,000,000 × g, and is among the commonly used and reported techniques in exosomes isolation. One of the potential advantages with this technique is reduced cost and contamination risks with separation reagents. It has a large sample capacity and yields large amounts of exosomes. Drawbacks include large time, non-scalable, chances of damaging vesicle, and low yield. Global companies, such as Thermo Fisher Scientific, offer a range of total exosomes isolation kits, which offer reagents for cell culture media, serum, plasma, urine, and other body fluids, such as cerebrospinal fluid, ascetic fluid, amniotic fluid, milk, and saliva, among others.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

The North American region holds one of the largest shares in the exosomes market, owing to better healthcare infrastructure, effective government policies, a huge base of multinational companies, and high awareness among people about diagnostics and healthcare. A large number of government-funded research studies have been conducted, regarding the role of drugs using exosomes in several kinds of cancers, such as melanoma, breast cancer, lung cancer, and pancreatic cancer, among others. Companies, like Merck and Exosome Diagnostic, have sponsored and collaborated with several universities, such as Yale Univeristy and Micihigan State University, to conduct clinical trials in the United States. Furthermore, these ventures are very well supported by government funding. The studies were mostly conducted for neoplasm.

Competitive Landscape
The exosomes market is highly competitive and consists of a number of major players. Companies, like Danaher (Beckman Coulter Inc.), Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, Novus Biologicals, Qiagen, Thermo Fisher Scientific Inc., among others, hold the substantial market share in the exosomes market.

Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- Report customization as per the client’s requirements
- 3 months of analyst support

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
10% Off

($4250)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019, provides an ...

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Transforming Growth Factor Beta 1 (TGFB1) - Pipeline Review, H2 2019SummaryTransforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-?1) is a polypeptide member of the transforming ...

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2019

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Pipeline Review, ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on